BMS eyes move to Kendall Square; Novartis faces Zometa jaw claims; U.K. watchdogs agree to rehash Ferring's cancer med Firmagon;

@FiercePharma: Top-read on FP Monday: Should deal-needy Pfizer target antibiotics specialist Cubist? Article | Follow @FiercePharma

@TracyStaton: ICYMI yesterday: @NovoNordisk CEO on the house that Victoza built and the future of diabetes R&D. Report | Follow @TracyStaton

@EricPFierce: Indian drugmaker, Marck Biosciences, ravaged by FDA warning letter for records kept on 'scratch paper.' Story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Reckitt Benckiser chief ahead of the consumer health curve, analysts say. Article | Follow @CarlyHFierce

> Bristol-Myers Squibb ($BMY) is eyeing a big move into office and lab space in Cambridge, MA, targeting 200,000 square feet in the Kendall Square area, a hotbed of drug development. Report

> The U.S. Sixth Circuit kicked Novartis ($NVS) back to trial court in a case over jaw injuries allegedly linked to its bone drugs Aredia and Zometa. Report

> U.K. cost-effectiveness gatekeepers agreed to reconsider Ferring Pharmaceuticals' prostate cancer treatment Firmagon (degarelix), previously rejected for routine use by the National Health Service. Report

> Indian drugmakers are facing more frequent bars against launching generic versions of patented drugs, with more than 10 so far this year, up from a half dozen for all of 2012. Report

Medical Device News

@FierceMedDev: Blood test for drug-resistant malaria strain shows promise. FierceDiagnostics story | Follow @FierceMedDev

@StacyALawrence: ICYMI yesterday: Abbott gets $20M from DoD to develop portable concussion test. Article | Follow @StacyALawrence

@VarunSaxena2: My photo was published in @indystar! George Will: Progressives as economic innocents. Story via IndyStar | Follow @VarunSaxena2

@EmilyWFierce: Medtronic sticks to its guns on Covidien and reports strongest quarterly U.S. sales growth in 5 years. More from Reuters | Follow @EmilyWFierce

> Leading U.S. hospital group target of external cyberattack. News

> Feds looking to fund clinical studies on cardiology, hip fracture and surgical mesh, among other topics. More

> Cheap, portable Dx device detects an array of medical and environmental conditions. Article

Biotech News

@FierceBiotech: Amgen successfully hits another PhIII goal line with kidney dialysis drug. Story | Follow @FierceBiotech

@JohnCFierce: On again: Novartis slashes ante, inks another Gamida Cell buyout pact in $635M leukemia deal. Article | Follow @JohnCFierce

@DamianFierce: If Zosano Pharma pulls off its IPO this week, it'll be the 52nd biotech to go public this year, per . | Follow @DamianFierce

@EmilyMFierce: Over-hyped headline, but excellent points here: You Are Not Nearly Scared Enough About Ebola. More | Follow @EmilyMFierce

> Novartis slashes ante, inks another Gamida Cell buyout pact in $635M leukemia deal. Story

> Lilly grabs a 'tentative' FDA OK for insulin treatment, but Sanofi still blocks its path. More

> Dermira pockets $51M to bankroll skin treatments. News

> Amgen successfully hits another PhIII goal line with kidney dialysis drug. Article

Biotech Research News

> Bacteria injection shrinks tumors in animals. Report

> Diabetes culprit may be a single enzyme. Story

> Researchers unveil lung-on-a-chip device. Article

> Ebola protein discovery could aid drug development. More

> Organovo 3-D printed liver tissue moves closer to market. Item

Pharma Manufacturing News

> FDA warning letter says Marck plant plagued by faked records and dead frogs. Report

> Sweden's Recipharm moves on Italy with $160M deal for Corvette. More

> Big Pharma stands back as little guys work on plant-based drugs and manufacturing. Report

> Sun Pharma recalls nearly 500,000 bottles of antibiotics. Story

> Sanofi shipping new malaria treatment manufactured from 'semisynthetic artemisinin.' Article

And Finally... Too many cancer screenings are given to elderly people likely to die within a decade, a study found. Report